Showing 4541-4550 of 5623 results for "".
- VSY Biotechnology Introduces Protectalon DUO Kithttps://modernod.com/news/vsy-biotechnology-introduces-protectalon-duo-kit/2478778/VSY Biotechnology has introduced the Protectalon DUO Kit, which is designed to help eye care professionals meet their OVD needs at different stages of cataract surgery with a single kit. The Protectalon DUO Kit features a Dual Pack containing one unit cohesive (14 mg/mL, 1.1 mL) and one un
- EyeCare Partners Acquires of Several Oklahoma-Based Independent Ophthalmology Practiceshttps://modernod.com/news/eyecare-partners-acquires-of-several-oklahoma-based-independent-ophthalmology-practices/2478776/EyeCare Partners has acquired multiple independent ophthalmology practices in Oklahoma City. The deal includes four ophthalmologists from three individual practices with six office locations and two ambulatory surgery centers. Epic Vision, Cataract Institute of Oklahoma, Precision Vision, and Eye
- More Adults with Vision Loss Seeking Help Staying Connected During Pandemichttps://modernod.com/news/more-adults-with-vision-loss-seeking-help-staying-connected-during-pandemic/2478772/Since the onset of COVID-19 those with visual impairments have faced disproportionate vulnerabilities from living in extended isolation. Newly released data has shown that clinical depression within the visually impaired community is being reported at nearly three times the level than the general
- Bausch + Lomb Completes Enrollment Of First Phase 3 Study For NOV03 (Perfluorohexyloctane)https://modernod.com/news/bausch-lomb-completes-enrollment-of-first-phase-3-study-for-nov03-perfluorohexyloctane/2478770/Bausch + Lomb and Novaliq announced the first of two phase 3 studies evaluating NOV03 as a first-in-class investigational drug with a novel mechanism of action to treat the signs and symptoms of dry eye disease (DED) associated with Meibomian gland dysfunction (MGD) has been completely enrolled w
- Printable Chart Suitable for Stay-at-Home Visual Evaluationhttps://modernod.com/news/printable-chart-suitable-for-stay-at-home-visual-evaluation/2478763/A chart that can be downloaded or printed and mailed to patients appears effective in helping determine visual acuity via telephone assessments, according to researchers in the UK, Reuters reported. “We are excited to be deve
- Sources: FDA Veteran Woodcock Being Considered to Lead Agency Under Bidenhttps://modernod.com/news/sources-fda-veteran-woodcock-being-considered-to-lead-agency-under-biden/2478764/Janet Woodcock, a 30-year veteran of the Food and Drug Administration, is being considered by President-elect Joe Biden to serve as commissioner of the agency, Bloomberg reported,
- Avellino Exceeds 1 Million COVID-19 Tests in 2020 and Welcomes New Executive Team Hires In 2021https://modernod.com/news/avellino-exceeds-1-million-covid-19-tests-in-2020-and-welcomes-new-executive-team-hires-in-2021/2478756/Avellino Lab USA announced that the company performed over 1 million AvellinoCoV2 COVID-19 tests since March 2020, and has further expanded the company’s executive team to drive additional development and commercial growth in 2021. Chief Scientific Officer, Nazneen Aziz, PhD, and Global Head of S
- Early Study Shows J&J’s One-Dose COVID-19 Vaccine Triggered Antibodies in all Participantshttps://modernod.com/news/early-study-shows-jjs-one-dose-covid-19-vaccine-triggered-antibodies-in-all-participants/2478759/Detailed phase 1/2a study findings published in the NEJM on Wednesday showed that all volunteers given Johnson & Johnson’s single-dose coronavirus vaccine Ad26.COV2.S had detectable neutralizing antibodies by day 57. In September, the company reported a preview of the interim results in
- US IDE Trial Results for Glaukos’ iStent infinite Show Reduction in IOPhttps://modernod.com/news/us-ide-trial-results-for-glaukos-istent-infinite-show-reduction-in-iop/2478754/Glaukos announced that 12-month U.S. Investigational Device Exemption (IDE) pivotal trial data showed that its iStent infinite Trabecular Micro-Bypass System achieved a substantial reduction in mean diurnal IOP in patients with open-angle glaucoma uncontrolled by prior surgical or medical therapy
- Johnson & Johnson Vision Releases New Guide to Help Slow the Progression of Myopia in Childrenhttps://modernod.com/news/johnson-johnson-vision-releases-new-guide-to-help-slow-the-progression-of-myopia-in-children/2478750/Johnson & Johnson Vision announced a new guide with recommendations for eye care professionals to assess, monitor and treat myopia in children. The guide, titled “Managing Myopia: A Clinical Response to the Growing Epidemic,” is a result of a year of collaboration with lead